Maverick Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Maverick Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,871	Closed	-$137K	–	927
2020 Q4	$137K	Buy	+1,871	New	+$139K	﹤0.01%	563
2020 Q2	–	Sell	-53,141	Closed	-$1.57M	–	726
2020 Q1	$1.57M	Sell	53,141 -74,295	-58%	-$2.51M	0.03%	221
2019 Q4	$4.61M	Sell	127,436 -40,187	-24%	-$1.23M	0.07%	138
2019 Q3	$4.56M	Sell	167,623 -45,657	-21%	-$1.18M	0.07%	170
2019 Q2	$5.13M	Buy	213,280 +23,840	+13%	+$605K	0.07%	157
2019 Q1	$5.01M	Sell	189,440 -95,660	-34%	-$2.27M	0.07%	198
2018 Q4	$5.57M	Sell	285,100 -14,490	-5%	-$284K	0.08%	153
2018 Q3	$5.87M	Buy	+299,590	New	+$5.7M	0.07%	159

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Maverick Capital's HZNP Position: Q1 2021 in Review

Maverick Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 1,871 shares — an estimated $137K sold.

Maverick Capital first reported a position in HZNP in Q3 2018 and held it in 8 quarters. The position peaked at $5.87M in Q3 2018. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

Maverick Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
Maverick Capital sold 1,871 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $137K.
Maverick Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 8 quarters.
Maverick Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.87M in Q3 2018.
516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Maverick Capital's 13F filing for Q1 2021, filed 17 May 2021.